BioLineRx (BLRX) Short term Debt (2011 - 2026)

BioLineRx's Short term Debt history runs 11 years deep, the most recent figure standing at $4.5 million for Q4 2025.

• In Q4 2025, Short term Debt changed 0.0% year-over-year to $4.5 million; the TTM figure through Dec 2025 stood at $4.5 million (changed 0.0% YoY), while the FY2025 annual figure was $4.5 million, changed 0.0% from the prior year.
• Short term Debt for Q4 2025 stood at $4.5 million, roughly flat from $4.5 million in the prior quarter.
• The five-year high for Short term Debt was $10.7 million in Q2 2024, with the low at $802000.0 in Q3 2022.
• The 5-year median for Short term Debt is $3.3 million (2021), against an average of $3.8 million.
• The sharpest annual moves came in 2022 and 2023: Short term Debt plunged 77.57% in 2022, then jumped 283.79% in 2023.
• BioLineRx's Short term Debt stood at $2.8 million in 2021, then slumped by 44.07% to $1.5 million in 2022, then surged by 103.96% to $3.1 million in 2023, then jumped by 42.42% to $4.5 million in 2024, then changed by 0.0% to $4.5 million in 2025.
• Business Quant data shows BLRX's Short term Debt at $4.5 million in Q4 2025, $4.5 million in Q3 2025, and $4.5 million in Q2 2025.